A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

Completed · Phase 2

Conditions studied: Glioblastoma, Glioblastoma Multiforme

In brief

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)

Key facts

Study ID
NCT01564914
Run by
Tracon Pharmaceuticals Inc.
People needed
22
Starts
2012-05-01
Expected to finish
2015-06-01
Last updated by the study team
2019-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.